- Source : Press Release
- Date : 2021-01-28
- Companies : UCB Pharma S.A.
UCB Community Health Fund Commits to 50 COVID-19 Support and Research Projects
· 170 applications for support projects and 43 applications for research projects were received
· 44 support projects and 6 research projects have been selected
· Focus on inspiring projects with a lasting positive impact, particularly on young people between 15-24 years old
· New call for projects to be announced in spring 2021
Brussels (Belgium) January 28, 2021 – 7:00 CET – Launched in June 2020, the UCB Community Health Fund directs funds to 50 impact-driven organizations and projects aiming to understand and reduce the medium- and long-term impact of the COVID-19 pandemic on the health of vulnerable young people.
The UCB Community Health Fund closed its first call for projects end of September 2020. A total of 170 applications for support projects and 43 applications for research projects were received from several countries where UCB operates.
The management committee of the Fund (managed by the King Baudouin Foundation) appointed independent selection committees with a broad geographical representation to assist in the selection of projects and award of funding. In total 44 support projects and 6 research projects were awarded for an amount of 2.440.000 EUR.
In the category of support projects, not-for-profit organizations and foundations in 5 continents will be able to start initiatives supporting homeless youth and preventing suicide and self-harm. Another group of awarded organizations will be mitigating health and psychosocial risks of COVID-19 to the most vulnerable and isolated youth. In Belgium, 22 not-for-profit organizations and foundations have been selected. A list of the projects is available on UCB's corporate website.
The grants for research projects are made available to hospitals and universities, studying the impact of COVID-19 on the health and wellbeing of young people in Belgium (4 projects) and the UK (2 projects).
“The high amount of applications confirmed there is a big need for support of vulnerable populations. While the selection committee was impressed with the good quality of proposed projects, we particularly focused on inspiring projects with a lasting positive impact, particularly on young people between 15-24 years old,” said Xavier Hormaechea, secretary-general of the UCB Community Health Fund. “We hope the funding will enable all the awarded organizations to continue the impressive work they are doing in their communities.”
The Community Health Fund is already liaising with the different supported organizations. Communication on the results of the projects and the research funded will follow.
New call for projects
While the first projects are being implemented, the management committee is already preparing the next call for projects. The targeted group of organizations and vulnerable people will be announced in spring when the new call for projects is expected to be launched.
About the UCB Community Health Fund
The UCB Community Health Fund was launched in 2020 in response to the COVID-19 pandemic. The fund, managed by the King Baudouin Foundation, aims to address health disparities among vulnerable populations, starting by contributing to understand and reduce the medium- and long-term impact of the COVID-19 pandemic on their physical, mental and social well-being. More specifically, the Fund wants to support vulnerable people, such as racial and ethnic minorities, children, older people, socio-economically disadvantaged persons, un(der)insures or those with certain medical conditions (not related to therapeutic areas nor assets) in the communities where UCB is active.
For further information UCB
Media Relations, UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7 500 people in approximately 40 countries, the company generated revenue of € 4.9 billion in 2019. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news
Forward looking statements UCB
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could delay, divert or change any of them this year and the next several years, that are difficult to predict, may be beyond UCB's control and could cause UCB's actual future financial results, goals, plans and objectives to differ materially from those that may be expressed in, or implied by, such forward-looking statements contained in this press release. Important factors that could result in such differences include: the global spread and impact of COVID-19, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees.
Additionally, information contained in this document shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction. UCB is providing this information as of the date of this document and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.
There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.
Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.
The updated financial guidance above does not reflect any potential impacts from the evolving COVID-19 pandemic. The company is following the development diligently to assess the financial significance of this pandemic to UCB.